New drug targets rare protein disease in early trial

NCT ID NCT06158854

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests an experimental drug called etentamig (ABBV-383) in adults with AL amyloidosis, a rare disease where abnormal proteins build up in organs. About 76 participants will receive the drug by infusion to see if it is safe and can control the disease. The trial has two parts to find the best dose and measure response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Etentamig (ABBV-383)
What this could lead to: If it works, this could provide a new treatment option to control AL amyloidosis by reducing harmful protein buildup.
What could go wrong: This is an early-phase trial with small numbers, so results may not apply broadly. Side effects are unknown and could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOGLOBULIN LIGHT CHAIN (AL) AMYLOIDOSIS

Contacts and locations

Locations

Alexandra General Hospital /ID# 255542
RECRUITING

Athens, Attica, 11528, Greece
Atrium Health Levine Cancer Institute /ID# 255074
RECRUITING

Charlotte, North Carolina, 28204, United States
Atrium Health Wake Forest Baptist Medical Center /ID# 255851
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Boston Medical Center /ID# 255066
RECRUITING

Boston, Massachusetts, 02118, United States
Box Hill Hospital /ID# 255199
RECRUITING

Box Hill, Victoria, 3128, Australia
CHU Limoges - Dupuytren 1 /ID# 255370
RECRUITING

Limoges, Franche-Comte, 87042, France
CHU Toulouse - Hopital Rangueil /ID# 255377
RECRUITING

Toulouse, Haute-Garonne, 31400, France
Columbia University Medical Center /ID# 255068
RECRUITING

New York, New York, 10032-3729, United States
Fondazione IRCCS Policlinico San Matteo /ID# 255655
RECRUITING

Pavia, 27100, Italy
IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255654
RECRUITING

Bologna, 40138, Italy
Icahn School of Medicine at Mount Sinai /ID# 255408
RECRUITING

New York, New York, 10029, United States
Japanese Red Cross Medical Center /ID# 256083
RECRUITING

Shibuya-ku, Tokyo, 150-8935, Japan
Kumamoto University Hospital /ID# 262579
RECRUITING

Kumamoto, Kumamoto, 8608556, Japan
Mayo Clinic - Rochester /ID# 255258
RECRUITING

Rochester, Minnesota, 55905-0001, United States
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255073
RECRUITING

New York, New York, 10065-6007, United States
Nagoya City University Hospital /ID# 256086
RECRUITING

Nagoya, Aichi-ken, 467-8602, Japan
Oregon Medical Research Center /ID# 255119
RECRUITING

Portland, Oregon, 97239, United States
Princess Alexandra Hospital /ID# 255202
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856
RECRUITING

Miami, Florida, 33136, United States
University of Washington /ID# 261581
RECRUITING

Seattle, Washington, 98109, United States
Vanderbilt University Medical Center. /ID# 273510
RECRUITING

Nashville, Tennessee, 37232, United States
Westmead Hospital /ID# 255200
RECRUITING

Westmead, New South Wales, 2145, Australia
Wisconsin Medical Center /ID# 255836
RECRUITING

Milwaukee, Wisconsin, 53226, United States